The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines

BACKGROUND: Imatinib mesylate, a selective inhibitor of Abl tyrosine kinase, is efficacious in treating chronic myeloid leukaemia (CML) and Ph+ acute lymphoblastic leukaemia (ALL). However, most advanced-phase CML and Ph+ ALL patients relapse on Imatinib therapy. Several mechanisms of refractoriness...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwanmesia, Patricia Mambou, Romanski, Annette, Schwarz, Kerstin, Bacic, Biserka, Ruthardt, Martin, Ottmann, Oliver G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654659/
https://www.ncbi.nlm.nih.gov/pubmed/19216789
http://dx.doi.org/10.1186/1471-2407-9-53

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654659/
https://www.ncbi.nlm.nih.gov/pubmed/19216789
http://dx.doi.org/10.1186/1471-2407-9-53

Ejemplares similares